NASDAQ: GALT - Galectin Therapeutics Inc.

Rentabilität für sechs Monate: -48.82%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan Galectin Therapeutics Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen Galectin Therapeutics Inc.

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.

weitere details
The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 2002-09-09
ISIN US3632252025
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://galectintherapeutics.com
Цена ао 1.64
Preisänderung pro Tag: +0.4478% (1.34)
Preisänderung pro Woche: +5.98% (1.27)
Preisänderung pro Monat: -19.88% (1.68)
Preisänderung über 3 Monate: +17.04% (1.15)
Preisänderung über sechs Monate: -48.82% (2.63)
Preisänderung pro Jahr: -65.58% (3.91)
Preisänderung über 3 Jahre: -12.6% (1.54)
Preisänderung über 5 Jahre: -10.86% (1.51)
Preisänderung seit Jahresbeginn: -33.37% (2.02)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 0 0
P/BV -1.77 0
P/E 0 0
EV/EBITDA -4.01 0
Gesamt: 2.5

Effizienz

Name Bedeutung Grad
ROA, % -145.62 0
ROE, % 68.17 10
Gesamt: 3.33

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -1.89 10
Gesamt: 9

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 0 0
Rentabilität Ebitda, % -98.47 0
Rentabilität EPS, % 166.44 10
Gesamt: 6
Weitere Details

Institutionen Volumen Aktie, %
Vanguard Group Inc 1941854 3.14
Osaic Holdings Inc 1251048 2.02
Blackrock Inc. 715351 1.16
Geode Capital Management, LLC 514416 0.83
Geneos Wealth Management, Inc. 412650 0.67
Atria Wealth Solutions, Inc. 249800 0.4
Morgan Stanley 185147 0.3
Wealthspire Advisors, LLC 183862 0.3
State Street Corporation 161440 0.26
Cambridge Investment Research Advisors Inc. 126581 0.2



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. Joel Lewis President, CEO & Director 907.72k 1970 (55 Jahre)
Mr. Jack W. Callicutt CPA CFO, Treasurer & Corporate Secretary 521.47k 1967 (58 Jahre)
Robert Tritt General Counsel N/A
Mr. Jeff Katstra Head of CMC & Pharmaceutical Development N/A
Ms. Beth Knowles Executive Assistant & Officer Manager N/A
Mr. Khurram Jamil M.D. Chief Medical Officer

Adresse: United States, Norcross. GA, 4960 Peachtree Industrial Boulevard - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://galectintherapeutics.com